Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study

Uzma Sarwar; Jeffrey B. Baker; Lisa Steffany Pinheiro Pereira; Ruth Paiano; Jon Finley; David Strong; Sandra Pagnussat; Shyam A. Patel; Y Liu; Emma Shittu; Olympia Evdoxia Anastasiou; Elena Kalinina; Kena A. Swanson; Annaliesa S. Anderson; Alejandra Gurtman; Iona Munjal

doi:10.1016/j.eclinm.2026.103767

January 29, 2026SHILAP Revista de lepidopterologíaOpen Access

Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study

View Full Paper

Ask AI

Bookmark

Share

Key Points

The bivalent RSVpreF vaccine demonstrates promising immunogenicity within the study cohort, showing robust immune responses.
Immunogenicity assessment revealed significant antibody production and immune activation over the study period.
In a multicenter, randomised, open-label phase 3 study, participants received the vaccine formulated in a multidose vial.
These findings support the vaccine's safety profile and may promote wider adoption in immunization practices.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

This phase 3 study evaluates immunogenicity and safety of a bivalent RSVpreF vaccine in healthy female participants, indicating its potential for broader use.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sarwar et al. (2026) studied this question.

synapsesocial.com/papers/69a75de9c6e9836116a2836d https://doi.org/10.1016/j.eclinm.2026.103767

View Full Paper

Ask AI

Bookmark

Share

Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading